Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity

University of Missouri (MU)

Status and phase: Withdrawn; Early Phase 1

Conditions: Insulin Resistance; Obesity; Autonomic Dysfunction

Treatments: Drug: Hyperinsulinemic, euglycemic infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT05518422

2090413

Details and patient eligibility

About

The aim of this project is to determine role for ET-1 in individuals with obesity.

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18-55 years of age
• Male sex
• Obese (BMI ≥30 kg/m2)

Exclusion criteria

• Female sex
• Current smoking/Nicotine use
• Nerve/neurologic disease
• Cardiovascular, hepatic, renal, respiratory disease
• Blood pressure ≥140/90 mmHg
• Diabetes
• Vigorous exercise >3 times/week
• Communication barriers
• taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Oral Bosentan

Experimental group

Treatment:

Drug: Hyperinsulinemic, euglycemic infusion